Health Care Sector Update for 09/14/2018: KALV, ARGX,CSBR,ALNY

Shutterstock photo

Top Health Care Stocks

JNJ -0.34%

PFE +0.21%

ABT -0.19%

MRK -0.72%

AMGN -1.28%

Health care stocks retreated Friday, including a nearly 0.4% decline for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 also were down just over 0.4% as a group while the Nasdaq Biotechnology index was falling nearly 0.7% today.

Among health care stocks moving on news:

(+) KalVista Pharmaceuticals ( KALV ) extended its day-long gains Friday afternoon, climbing almost 16% in late trade, after narrowing its fiscal Q1 net loss and revenue soared compared with the same quarter last year. Net loss for early-stage biotech company was $0.47 per share on $3.7 million in revenue during the three months ended July 31, improving on a $0.51 per share loss in the year-ago period on just $100,000 in revenue. The market largely ignored analyst estimates expecting a $0.33 per share net loss for the company on $3.81 million in revenue. The company also said it has selected its KVD900 product candidate to advance to a phase 2 proof-of-concept clinical trial as a potential on-demand treatment of acute attacks in patients with hereditary angioedema.

In other sector news:

(+) Champions Oncology ( CSBR ) sped to a four-year high on Friday, rising almost 30% to its highest share price since June 2014 at $11.00 each after the biotech company reported a $0.05 per share profit during the three months ended July 31, reversing a $0.01 per share net loss in the year-ago period, after revenue rose 23.7% year over year to $6.2 million. That beat the single-analyst call expecting a $0.01 per share profit on $5.64 million in revenue.

(+) argenx SE ( ARGX ) climbed sharply on Friday, rising almost 8% at one point, after analysts at Stifel Nicolaus initiated coverage of the biopharmaceuticals company with a Buy rating and a $139 price target.

(-) Alnylam Pharmaceuticals ( ALNY ) was more than 1% higher Friday afternoon, giving back a more than 4% gain, earlier in the session that followed the company said its Patisiran drug candidate showed potential to treat polyneuropathy and may favorably may favorably impact certain cardiac manifestations of hereditary transthyretin-mediated amyloidosis during Phase III testing.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , US Markets
Referenced Symbols: KALV , CSBR , ARGX , ALNY

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities

Research Brokers before you trade

Want to trade FX?